Please assess the completion status of the following clinical trial:

Trial Title: Metronidazole Pharmacokinetics (PK) in Premature Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age \<32 weeks at the time of enrollment.~* Postnatal age \<91 days at the time of enrollment.~* Sufficient venous access to permit administration of study medication.~* Infant suspected to have a serious infection and from whom a blood culture has been obtained within 96 hours of study entry.~Exclusion Criteria:~* History of anaphylaxis to metronidazole or other nitroimidazole derivatives (e.g., tinidazole).~* Previous exposure to metronidazole in the week prior to study.~* Previous participation in the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 90 Days
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).